LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Home・Akcijų sąrašas・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Uždarymo kaina

1.69 4.97

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.58

Max

1.69

Pagrindiniai rodikliai
By Trading Economics
Pajamos	13M -43M
Pelno marža	-2,190.837
Darbuotojai	171
EBITDA	17M -42M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+79.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-8M 96M
Ankstesnė atidarymo kaina	-3.28
Ankstesnė uždarymo kaina	1.69

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

1.43 / 1.6 Palaikymas ir pasipriešinimas

Pliant Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-26 23:56; UTC

Uždarbis

WiseTech Lifts Dividend as Its Annual Profit Rises 30% -- Update

2025-08-26 23:48; UTC

Uždarbis

Woolworths Annual Profit Falls, Cuts Dividend

2025-08-26 23:41; UTC

Uždarbis

WiseTech Lifts Dividend as Its Annual Profit Rises 30%

2025-08-26 23:58; UTC

Uždarbis

China Resources Land: Real-Estate Sector Faces Structural Challenges, but Homebuying Demand Gradually Returning >1109.HK

2025-08-26 23:57; UTC

Uždarbis

China Resources Land: 1H Results Buoyed by Investment Property & Asset Management Business >1109.HK

2025-08-26 23:55; UTC

Uždarbis

China Resources Land 1H Net CNY11.88B Vs. Net CNY10.22B >1109.HK

2025-08-26 23:55; UTC

Uždarbis

China Resources Land 1H Rev CNY94.92B Vs. CNY79.19B >1109.HK

2025-08-26 23:48; UTC

Uždarbis

Karoon Energy Interim Dividend 2.4 Australian Cents/Security

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Underlying Net Profit US$45 Million, Down 61% on Year

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Revenue US$308.3 Million, Down 25% on Year

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Net Profit US$71 Million, Up 15% on Year

2025-08-26 23:46; UTC

Rinkos pokalbiai

Nikkei May Trade in Range Amid US Tariff Uncertainty -- Market Talk

2025-08-26 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments -- Market Talk

2025-08-26 23:35; UTC

Uždarbis

Karoon Energy Expects Expenditure of US$80 Million-US$90 Million Over 2030-2034

2025-08-26 23:35; UTC

Uždarbis

Karoon Energy Expects Expenditure of US$55 Million-US$65 Million for Projects in 2026

2025-08-26 23:34; UTC

Uždarbis

Karoon Energy: Baúna Revitalization, Life Extension Projects Initiated

2025-08-26 23:34; UTC

Uždarbis

Karoon Energy: Baúna Project Economic Field Life Extends to 2039

2025-08-26 23:33; UTC

Uždarbis

Karoon Energy Raises Baúna Project 2P Reserves by 13.7 Million Bbls

2025-08-26 23:23; UTC

Uždarbis

WiseTech: FY25 Ebitda Margin Exit Run Rate 52%>WTC.AU

2025-08-26 23:22; UTC

Uždarbis

WiseTech: New CargoWise Commercial Model Ready for Rollout>WTC.AU

2025-08-26 23:21; UTC

Uždarbis

WiseTech Says Integration of e2open Is on Track>WTC.AU

2025-08-26 23:14; UTC

Uždarbis

WiseTech Expects FY26 Ebitda Margin of 40-41%>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Ebitda Growth of 44-53%>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Ebitda of $550M-$585M>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Revenue Growth of 79-85%>WTC.AU

2025-08-26 23:12; UTC

Uždarbis

WiseTech Expects FY26 Revenue of $1.39B-$1.44B>WTC.AU

2025-08-26 23:11; UTC

Uždarbis

WiseTech FY Ebitda Margin Ex-e2open Costs 53%>WTC.AU

2025-08-26 23:11; UTC

Uždarbis

WiseTech FY Ebitda Margin 49% Vs. 48%>WTC.AU

2025-08-26 23:10; UTC

Uždarbis

WiseTech FY Ebitda $381.6M Vs. $325.0M>WTC.AU

2025-08-26 23:09; UTC

Uždarbis

WiseTech Global Declares Dividend of $0.077 >WTC.AU

Akcijų palyginimas

Kainos pokytis

Pliant Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

79.87% į viršų

12 mėnesių prognozė

Vidutinis 2.68 USD 79.87%

Aukščiausias 4 USD

Žemiausias 1.7 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pliant Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Pliant Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.43 / 1.6Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.